Slingshot members are tracking this event:

Intercept Pharmaceuticals (ICPT) plans to commence Phase 2 INT-767 trial in the second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ICPT Community voting in process

Additional Information

Additional Relevant Details Update on Nov 1 2017: Intercept has decided to deprioritize its INT-767 development program for the foreseeable future.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 17, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Int-767, Phase 2